For treating cancer cells, targeting nociceptive TRP channel activities by using multiple TRP-specific antagonists facilitates elimination or reduction of cancer development; for instance, treatment with SKF96365 and 2-aminoethoxydiphenylborate (2-APB) blocks lung cancer cell growth via inhibiting nociceptive TRPC1 [13]. Here, TRPC1 is linked to cancer.